Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| A antigen hexaose type 2 | A Antigen Hexaose Type 2 is a antigen hexaose type 2 employed in the research of autoimmune disorders such as rheumatoid arthritand psoriasis. Synonyms: GalNAca-3(fuca-2)Galb-4GlcNAcb-3Galb-4Glc. CAS No. 30461-82-6. Molecular formula: C40H68N2O30. Mole weight: 1056.96. |  |
| B antigen hexaose | B antigen hexaose is a compound commonly for the research of various diseases playing a vital role in the field of immunology, used in detecting and determining the presence of the B antigen on red blood cells. Synonyms: Gal-a-1,3(Fuc-a-1,2)Gal-b-1,4GlcNAc-b-1,3Gal-b-1,4Glc. Molecular formula: C38H65NO30. Mole weight: 1015.93. | |
| Difucosyllacto-N-hexaose (a) | Difucosyllacto-N-hexaose (a) is an indispensable molecule widely employed in the biomedical sector due to its inherent therapeutic attributes. Its efficacy in tackling various ailments such as cancer and autoimmune disorders has been established through rigorous examination. Notably, this compound serves as an unrivaled asset in precise medical examinations elucidating individualized pharmacological targets. Synonyms: DFLNH (a); difucosyl-para-lacto-N-neo-hexaose; β -Gal-(1-4)[α -Fuc-(1-3)]-β -GlcNAc-(1-3)-β -Gal-(1-4)[α -Fuc(1-3)]-β -GlcNAc(1-3)-β -Gal-(1-4)-Glc; Fuc (a1-3)[Gal (b1-4)]GlcNAc (b1-3)Gal (b1-4)[Fuc (a1-3)]GlcNAc (b1-3)Gal (b1-4)Glc; 6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)-[beta-D-galacto-hexopyranosyl-(1->4)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose. Grades: ≥90%. CAS No. 64396-27-6. Molecular formula: C52H88N2O39. Mole weight: 1365.25. | |
| Difucosyllacto-N-hexaose b | Difucosyllacto-N-hexaose b is an extraordinary biomedical marvel meticulously designed to study a plethora of ailments like microbial infections instigated by select bacteria and viruses. Synonyms: DFLNH (b); difuco-lacto-N-hexaose; Difucosyllacto-N-neohexaose II; D-Glucose, O-6-deoxy-α-L-galactopyranosyl-(1->3)-O-[β-D-galactopyranosyl-(1->4)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1->6)-O-[O-6-deoxy-α-L-galactopyranosyl-(1->4)-O-[β-D-ga lactopyranosyl-(1->3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1->3)]-O-β-D-galactopyranosyl-(1->4)-. Grades: ≥95%. CAS No. 98359-76-3. Molecular formula: C52H88N2O39. Mole weight: 1365.25. | |
| Difucosyllacto-N-hexaose (b) | Difucosyllacto-N-hexaose (b) is a compound widely employed sector, used for studying a plethora of afflictions, including cancer and viral infections. As an adjuvant, this compound exerts its influence by amplifying the immune response, thus rendering it indispensable in the realm of drug discovery for immunotherapy and vaccine formulation. Synonyms: DFLNH (b); Cluster Lewis x-Lewis a octasaccharide branched. Molecular formula: C52H88N2O39. Mole weight: 1365.25. | |
| Difucosyllacto-N-hexaose (c) | Difucosyllacto-N-hexaose (c) is a compound skillfully targeting select proteins implicated in cellular adhesion, rendering it extensively employed in the research of anti-inflammatory and anti-infective therapeutic advancements. Synonyms: DFLNH (c); Lewis b octasaccharide branched; O-6-Deoxy-alpha-L-galactopyranosyl-(1?2)-O-beta-D-galactopyranosyl-(1?3)-O-[6-deoxy-alpha-L-galactopyranosyl-(1?4)]-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1?3)-O-[O-beta-D-galactopyranosyl-(1?4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1?6)]-O-beta-D-galactopyranosyl-(1?4)-D-glucose. Grades: 95%. CAS No. 443361-17-9. Molecular formula: C52H88N2O39. Mole weight: 1365.25. | |
| DIFUCOSYLLACTO-N-NEO-HEXAOSE | Heterocyclic Organic Compound. CAS No. 115236-57-2. Catalog: ACM115236572. |  |
| Difucosyl-para-lacto-N-hexaose-APD-HSA | | |
| Difucosyl-para-lacto-N-hexaose I | Difucosyl-para-lacto-N-hexaose I is an indispensable constituent forged from fucosylated oligosaccharides. Displaying an extraordinary configuration, Difucosyl-para-lacto-N-hexaose I finds applicability in the research of sundry afflictions such as cancer and autoimmune maladies. Synonyms: Lewis b octasaccharide linear; DFpLNH. Molecular formula: C53H91N2O38. Mole weight: 1364.28. | |
| Difucosyl-para-lacto-N-hexaose II | Difucosyl-para-lacto-N-hexaose II, a highly promising biomedicine, stands at the forefront of diverse disease treatments. Showcasing its prowess, this potent compound exhibits immense potential in honing in on selective receptors implicated in cancer metastasis, thus paving the way for the advancement of targeted therapeutic approaches. Moreover, its indispensability arises from its pivotal role in modulating immune responses, offering efficacious treatment to autoimmune maladies. Synonyms: DFpLNH II; Dimeric Lewis a-Lewis x octasaccharide linear. Grades: ≥95%. CAS No. 64309-01-9. Molecular formula: C52H88N2O39. Mole weight: 1365.25. | |
| Difucosyl-para-lacto-N-hexaose III | | |
| Disialyllacto-N-hexaose I | Disialyllacto-N-hexaose I is a profound biomedical compound, playing a pivotal role in the research of diverse ailments by effectively targeting a spectrum of receptors linked to both malignant neoplasms and infection. Synonyms: DSLNH-I; O-(N-Acetyl-a-neuraminosyl)-(2?3)-O-b-D-galactopyranosyl-(1?3)-O-2-acetamido-2-deoxy-b-D-glucopyranosyl-(1?3)-O-[O-(N-acetyl-a-neuraminosyl)-(2?6)-O-b-D-galactopyranosyl-(1?4)-2-acetamido)-2-deoxy-b-D-glucopyranosyl-(1?6)]-O-b-D-galactopyranosyl-(1?4)-D-glucose. CAS No. 137636-98-7. Molecular formula: C62H102N4O47. Mole weight: 1655.47. | |
| Disialyl, monofucosyllacto-N-hexaose | Disialyl, monofucosyllacto-N-hexaose is a biomedical product, exhibiting remarkable ability to selectively target and impede the proliferation of malignant cells. Furthermore, its utilization as a tool for investigating glycobiological phenomena and cellular surface interactions enhances our understanding of intricate biological mechanisms. Synonyms: DSFLNH; Disialyllactomonofucosyl-N-hexaose; O-(N-Acetyl-α-neuraminosyl)-(2?6)-O-β-D-galactopyranosyl-(1?4)-O-2-(acetylamino)-2-deoxy-β-D-Glucopyranosyl-(1?6)-O-[O-(N-acetyl-α-neuraminosyl)-(2?3)-O-β-D-galactopyranosyl-(1?4)-O-[6-deoxy-α-L-galactopyranosyl-(1?3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1?3)]-O-β-D-galactopyranosyl-(1?4)-D-glucose. CAS No. 263916-84-3. Molecular formula: C68H112N4O51. Mole weight: 1801.61. | |
| Globo-H hexaose | Globo-H hexaose is an intricate carbohydrate-derived compound, finding its application as a research tool in unraveling mysteries pertaining to specific ailments such as cancer. Synonyms: Fuc-a-1,2-Gal-b-1,3-GalNAc-b-1,3-Gal-a-1,4-Gal-b-1,4-Glc. Grades: 90%. CAS No. 77538-31-9. Molecular formula: C38H65NO30. Mole weight: 1015.91. | |
| Lacto-N-difucohexaose II | Lacto-N-difucohexaose II, a carbohydrate compound prevalent in the biomedical industry for research purposes, has been found to impede pathogen adhesion to human intestinal cells. This realization has spurred speculation on the potential of Lacto-N-difucohexaose II as a viable candidate in the development of drug interventions for infectious maladies afflicting the gut. Equally exciting, Lacto-N-difucohexaose II may also offer promise as a cancer treatment. Synonyms: LNDFH II; Lewis A hexaose; D-Glucose, O-6-deoxy-alpha-L-galactopyranosyl-(1-3)-O-(O-6-deoxy-alpha-L-galactopyranosyl-(1-4)-O-(beta-D-galactopyranosyl-(1-3))-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-beta-D-galactopyranosyl-(1-4))-; β-D-Gal-(1-3)-[α-L-Fuc-(1-4)]-β-D-GlcNAc-(1-3)-β-D-Gal-(1-4)-[α-L-Fuc-(1-3)]-D-Glc. Grades: ≥95%. CAS No. 62258-12-2. Molecular formula: C38H65NO29. Mole weight: 999.91. | |
| Lacto-N-hexaose | Lacto-N-hexaose is an esteemed and extensively employed compound with field assuming a pivotal position in the research of numerous afflictions such as gastrointestinal disorders and viral infections. By virtue of its distinctive structural composition, Lacto-N-hexaose showcases an unparalleled therapeutic capacity, thereby stimulating optimistic prospects for the creation of innovative pharmaceutical compounds intended to study these exigencies. Synonyms: LNH; LNThex; D-Glucose, O-beta-D-galactopyranosyl-(1-3)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-O-(O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6))-O-beta-D-galactopyranosyl-(1-4)-; β-D-Gal-(1?3)-β-D-GlcNAc-(1?3)-(β-D-Gal-[1?4]-β-D-GlcNAc-[1?6])-β-D-Gal-(1?4)-D-Glc. Grades: ≥95%. CAS No. 64003-51-6. Molecular formula: C40H68N2O31. Mole weight: 1072.96. | |
| Lacto-N-neodifucohexaose | Lacto-N-neodifucohexaose is a remarkable and prodigious compound, unveiling its colossal potentiality in an extensive array of ailments' therapies. Profoundly deviating from the conventional medicine panorama, this extraordinary compound manifests its profound therapeutic proficiencies through the prophylaxis of bacterial invasions is amplification of the immune system's prowess and alleviation of inflammation. Emanating as an epitome of immunomodulation, it has exhibited compelling outcomes when studying selected malignancies and gastrointestinal disorders. Furthermore, Lacto-N-neodifucohexaose serves as an invaluable diagnostic apparatus, proficiently identifying peculiar pathogens alongside distinct markers linked to sundry diseases. Synonyms: Gal-b-1-4(Fuc-a-1-3)GlcNAc-b-1-3Gal-b-1-4(Fuc-a-1-3)Glc; Lewis X hexaose; LNnDH. Molecular formula: C38H65NO29. Mole weight: 999.93. | |
| Monofucosyllacto-N-hexaose I | Monofucosyllacto-N-hexaose I is a formidable candidate for studying multifarious medical afflictions such as Crohn's diseases. This compound is a complex harmony of fucose and lactose, manifesting propitious anti-inflammatory attributes. Synonyms: MFLNH I; Lewis c heptasaccharide branched; O-6-Deoxy-alpha-L-galactopyranosyl-(1-2)-O-beta-D-galactopyranosyl-(1-4)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-O-[O-beta-D-galactopyranosyl-(1-4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6)]-O-beta-D-galactopyranosyl-(1-4)-D-glucose; D-Glucose, O-6-deoxy-α-L-galactopyranosyl-(1?2)-O-β-D-galactopyranosyl-(1?4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1?3)-O-[O-β-D-galactopyranosyl-(1?4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1?6)]-O-β-D-galactopyranosyl-(1?4)-. Grades: ≥90%. CAS No. 341511-38-4. Molecular formula: C46H78N2O35. Mole weight: 1219.10. | |
| Monofucosyllacto-N-hexaose II | Monofucosyllacto-N-hexaose II is a revolutionary biomedical product with remarkable capacity to target and modulate cellular pathways linked to cancer, autoimmune disorders and infectious diseases. It aids in related research and drug development. Synonyms: MFLNH II; Lewis a heptasaccharide branched. CAS No. 1240020-24-9. Molecular formula: C46H78N2O35. Mole weight: 1219.10. | |
| Monofucosyllacto-N-hexaose III | Monofucosyllacto-N-hexaose III, an imperative biomedicine, serves as a remarkable therapeutic solution within the biomedical domain. By selectively targeting distinct pharmaceuticals, this exquisite composition plays a vital role in combating an array of ailments comprising cancer, inflammation, and microbial infections. Synonyms: MFLNH III; fucosyllacto-N-hexaose III; alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-D-Glcp; 6-deoxy-alpha-L-galactopyranosyl-(1->3)-[beta-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->6)-[beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)]-beta-D-galactopyranosyl-(1->4)-D-glucopyranose; Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc. Grades: ≥90%. CAS No. 96656-34-7. Molecular formula: C46H78N2O35. Mole weight: 1219.12. | |
| Monofucosyl-para-lacto-N-hexaose I | Monofucosyl-para-lacto-N-hexaose I is a unique compound widely employed in the research of various diseases and conditions such as cancer, inflammation and autoimmune disorders. Synonyms: MFpLNH I; Lewis c heptasaccharide linear. Molecular formula: C46H78N2O35. Mole weight: 1219.12. | |
| Monofucosyl-para-lacto-N-hexaose II | Monofucosyl-para-lacto-N-hexaose II is an avant-garde compound, meticulously harnessed for the research of sundry diseases. This exalted substance aptly assumes the role of an inhibitor. Synonyms: MFpLNH I; Lewis a heptasaccharide linear. CAS No. 115236-59-4. Molecular formula: C46H78N2O35. Mole weight: 1219.10. | |
| Monofucosyl-para-lacto-N-hexaose IV | Monofucosyl-para-lacto-N-hexaose IV, a remarkable compound, serves as a pivotal asset within the biomedical realm. Embracing its inherent medicinal prowess, this extraordinary substance exhibits unparalleled capabilities in combatting a myriad of maladies. Synonyms: MFpLNH IV; fucosyl-p-lacto-N-hexaose IV; Fucosyl-para-lacto-N-hexaoseIV; β -Gal-(1?3)-β -GlcNAc-(1?3)-β -Gal-(1-4)(α -Fuc-[1?3])-β -GlcNAc-(1?3)-β -Gal-(1?4)-Glc; D-Glucose, O-6-deoxy-α -L-galactopyranosyl-(1->3)-O-[O-β -D-galactopyranosyl-(1->3)-O-2-(acetylamino)-2-deoxy-β -D-glucopyranosyl-(1->3)-β -D-galactopyranosyl-(1->4)]-O-2-(acetylamino)-2-deoxy-β -D-glucopyranosyl-(1->3)-O-β -D-galactopyranosyl-(1->4)-. Grades: ≥95%. CAS No. 115236-58-3. Molecular formula: C46H78N2O35. Mole weight: 1219.12. | |
| Monosialyl, difucosyllacto-N-hexaose I | Monosialyl, difucosyllacto-N-hexaose I is a biomedical substance, showcasing profound significance in modulating cellular interactions through its targeted receptor affinity. This compound's inhibitory prowess illuminates promising prospects for studying inflammation, as well as autoimmune disorders and select malignancies. Molecular formula: C63H105N3O47. Mole weight: 1656.50. | |
| Monosialyllacto-N-hexaose | Monosialyllacto-N-hexaose is an invaluable compound significantly employed in the biomedical sector, aiding in studying afflictions of neurological nature encompassing Alzheimer's ailment, stroke, as well as traumatic brain injury. Molecular formula: C51H85N3O39. Mole weight: 1364.22. | |
| Monosialyllacto-N-hexaose II | | |
| Monosialyllacto-N-hexaose III | | |
| Monosialyl, monofucosyl-(1-2)-lacto-N-hexaose | | |
| Monosialyl, monofucosyl-(1-3)-lacto-N-hexaose | | |
| Monosialyl, monofucosyllacto-N-hexaose I | Monosialyl, monofucosyllacto-N-hexaose I, an extraordinary compound, is artfully invigorates the intricate web of neural complexities, aiding in studying the relentless tide of neurological disorders such as Alzheimer's and Parkinson's. Molecular formula: C57H95N3O43. Mole weight: 1510.36. | |
| N-Acetylneuraminyl-L-lacto-N-neo-hexaosefrom huma | Heterocyclic Organic Compound. CAS No. 118023-83-9. Molecular formula: C51H85N3O39. Mole weight: 1364.22. Catalog: ACM118023839. | |
| p-Lacto-N-hexaose | p-Lacto-N-hexaose is a multifaceted compound, serving as a tool for studying gastrointestinal afflictions. Derived from lactose and hailed as an oligosaccharide, this enigmatic compound exhibits prebiotic characteristics that invigorate the proliferation of advantageous intestinal microorganisms. Synonyms: pLNH; para-Lacto-N-hexaose; Gal-b-1,3GlcNAc-b-1,3-Gal-b-1,4-GlcNAc-b-1,3-Gal-b-1,4-Glc; β-D-Gal-(1-3)-β-D-GlcNAc-[1-3]-β-D-Gal-(1-4)-β-D-GlcNAc-(1-3)-β-D-Gal-(1-4)-D-Glc; O-beta-D-Galactopyranosyl-(1-3)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-O-beta-D-galactopyranosyl-(1-4)-O-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-3)-O-beta-D-galactopyranosyl-(1-4)-D-glucose. Grades: ≥90%. CAS No. 64331-48-2. Molecular formula: C40H68N2O31. Mole weight: 1072.96. | |
| SSEA-4 hexaose | SSEA-4 Hexaose is an extraordinary compound origining from the SSEA-4 antigen, used for studying diverse ailments, encompassing the realms of cancer to neurodegenerative disorders. Synonyms: Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glc; Stage-Specific Embryonic Antigen-4. Molecular formula: C43H71N2O34Na. Mole weight: 1183.01. | |
| Trifucosyllacto-N-hexaose | Trifucosyllacto-N-hexaose is a biomedical compound for studying infections, allergies and metabolic aberrations. Synonyms: TFLNH; Trifucosyllacto-N-Hexaose a. CAS No. 11688-09-1. Molecular formula: C58H98N2O43. Mole weight: 1511.39. | |
| Trifucosyllacto-N-hexaose a | Heterocyclic Organic Compound. CAS No. 11688-09-1. Molecular formula: C58H98N2O43. Mole weight: 1511.39. Catalog: ACM11688091. | |
| Trifucosyl-p-lacto-N-hexaose | Trifucosyl-p-lacto-N-hexaose, a burgeoning contender in cancer therapy, showcases multifaceted potential as a profound inhibitor of galectin-3. A notorious instigator of cancer cell proliferation and subversive evasion of the immune system. Moreover, its efficacious ability in awakening robust immunological reactions against cancer cells insinuates the possibility of being the next big immunotherapy drug. Its intricate composition and inscrutable mode of operation demand critical assessment. Synonyms: TFpLNH; α -Fuc-(1?2)-β -Gal-(1?3)-[α -Fuc-(1?4)]-β -GlcNAc-(1?3)-β -Gal-(1?4)-[α -Fuc-(1?3)]-β -GlcNAc-(1?3)-β -Gal-(1?4)-Glc; Leb-Lex-L nonasaccharide; Trifucosyl-para-lacto-N-hexaose I; Fuc-a-1,2-Gal-b-1,3(Fuc-a-1,4)GlcNAc-b-1,3-Gal-b-1,4(Fuc-a-1,3)GlcNAc-b-1,3-Gal-b-1,4-Glc; D-Glucose, O-6-deoxy-α-L-galactopyranosyl-(1->3)-O-[O-6-deoxy-α-L-galactopyranosyl-(1->4)-O-[O-6-deoxy-α-L-galactopyranosyl-(1->2)-β-D-galactopyranosyl-(1->3)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1->3)-β-D-galactopyranosyl-(1->4)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1->3)-O-β-D-galactopyranosyl-(1->4)-; Trifuco para-lacto-N-hexaose I. Grades: ≥90%. CAS No. 120864-60-0. Molecular formula: C58H98N2O43. Mole weight: 1511.39. | |
| Alpha-fuc-[1->2]-beta-gal-[1->3]-(alpha-fuc-[1->4])-beta-glcnac-[1->3]-beta-gal-[1->4]-(alpha-fuc-[1->3])-beta-glcnac-[1->3]-beta-gal-[1->4]-glc | Heterocyclic Organic Compound. Alternative Names: Leb-Lex-L nonasaccharide, Trifucosyl-para-lacto-N-hexaose, |A-Fuc-(1 inverted exclamation marku2)-|A-Gal-(1 inverted exclamation marku3)-[|A-Fuc-(1 inverted exclamation marku4)]-|A-GlcNAc-(1 inverted exclamation marku3)-|A-Gal-(1 inverted exclamation marku4)-[|A-Fuc-(1 inverted exclamation marku3)]-|A-GlcNAc-(1 inverted exclamation marku3)-|A-Gal-(1 inverted exclamation marku4)-Glc, 120864-60-0. CAS No. 120864-60-0. Molecular formula: C42H72N2O29. Mole weight: 1069.02. Purity: 0.96. IUPACName: N-[(2S,3R,4R,5S,6R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-5-acetamido-6-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydrox. Canonical SMILES: CC1C (C (C (C (O1)OC2C (OC (C (C2OC3C (C (C (C (O3)CO)O)O)OC4C (C (C (C (O4)C)O)O)O)NC (=O)C)OC5C (C (OC (C5O)OC6C (OC (C (C6OC7C (C (C (C (O7)C)O)O)O)NC (=O)C)OC8C (OC (C (C8O)O)OC9C (OC (C (C9O)O)O)CO)CO)CO)CO)O)CO)O)O)O. Catalog: ACM120864600. | |
| Globo-H hexasaccharide-sp-biotin | Globo-H Hexasaccharide-sp-biotin is a biomedical product used to aid in the treatment and detection of certain types of cancer, particularly breast and ovarian cancer. It acts as a therapeutic agent by targeting and delivering drugs to cancer cells while sparing healthy cells. Additionally, it serves as a diagnostic tool by enabling the visualization of cancer cells through a process known as immunoassay. Synonyms: Globo-H Hexaose-b-NAc-Spacer-biotin. Grades: 90%. Molecular formula: C61H102N8O35S. Mole weight: 1539.56. | |
| lacto-N-biosidase | The enzyme from Streptomyces specifically hydrolyses the terminal lacto-N-biosyl residue (β-D-Gal-(1?3)-D-GlcNAc) from the non-reducing end of oligosaccharides with the structure β-D-Gal-(1?3)-β-D-GlcNAc-(1?3)-β-D-Gal-(1?R). Lacto-N-hexaose (β-D-Gal-(1?3)-β-D-GlcNAc-(1?3)-β-D-Gal-(1?3)-β-D-GlcNAc-(1?3)-β-D-Gal-(1?4)-D-Glc) is hydrolysed to form first lacto-N-tetraose plus lacto-N-biose, with the subsequent formation of lactose. Oligosaccharides in which the non-reducing terminal Gal or the penultimate GlcNAc are replaced by fucose or sialic acid are not substrates. Asialo GM1 tetraose (β-D-Gal-(1?3)-β-D-GalNAc-(1?3)-β-D-Gal-(1?4)-D-Glc) is hydrolysed very slowly, but lacto-N-neotetraose (β-D-Gal-(1?4)-β-D-GalNAc-(1?3)-β-D-Gal-(1?4)-D-Glc) is not a substrate. Group: Enzymes. Enzyme Commission Number: EC 3.2.1.140. CAS No. 146359-52-6. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3823; lacto-N-biosidase; EC 3.2.1.140; 146359-52-6. Cat No: EXWM-3823. |  |
| Tflnh[a] | Heterocyclic Organic Compound. Alternative Names: TFLNH[A];TRIFUCOSYLLACTO-N-HEXAOSE A;trifucosyllacto-N-hexaose A from*human milk;Trifucosyllacto-N-hexaose a, Human Milk;N-[2-[2-[[3-acetamido-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyo. CAS No. 116883-09-1. Molecular formula: C58H98N2O43. Mole weight: 1511.39. Purity: 0.96. IUPACName: N-[2-[[4-[3-acetamido-4-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(1,2,4,5-tetrahydroxy-6-oxohexan-3-yl)oxyoxan-2-yl]met. Density: 1.73g/cm³. Catalog: ACM116883091. | |
Our database is helping our users find suppliers everyday.
